Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Anaesthesia is a medical procedure which reduces the pain during surgery and other painful medical processes. It initiates the loss of awareness and sensation to the patient, which helps surgeon for carrying entire surgery. The anaesthesia is a drug which prevents pain during a surgical procedure. The anaesthesia type used for surgeries is govern by various factors like length and type of the surgery, patient health and preference of the surgeon doctor and patients. There are three types of anaesthesia drugs are local anaesthesia, general anaesthesia and regional anaesthesia. Local anaesthesia is injected in the tissues to numb the specific part of the body for minor surgical operations. In general anaesthesia, the patient is totally unconscious and haven’t feel any sense in the body and regional anaesthesia is comprised of injection near the cluster nerve for numbness of body parts.
The Asia Pacific local anaesthetic drug market is witnessing lucrative growth during the forecast period of 2021-2027. The local anaesthetic medicines cause the reversible loss of sensation or pain in specific body part which is acquired by topical application or injection of local anaesthetics. The major factors like growing number of surgeries is propelling growth of Asia Pacific local anaesthetic drug market. The emergence of modern and effective drugs is also refuelling growth of Asia Pacific local anaesthetic drug market. The increasing healthcare expenditure in developing countries is also boosting the growth of Asia Pacific local anaesthetic drug market. However, regulatory issues by government is hampering the growth of Asia Pacific local anaesthetic drug market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the local anaesthetic drug market. In addition, complete analysis of changes on local anaesthetic drug expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Asia Pacific economies, international trade, business investments, GDP and marketing strategies of key players present in the market. There is slight slow growth of local anaesthetic drug market is experienced during the COVID-19 situation as there is several restraining factors like mismatch between demand and supply due to complete shutdown in many countries which hampered the transportation of general anaesthetic drugs. The several surgical procedures are post ponded during the time of COVID-19 pandemic. However, activities are resuming and all the pending surgeries are being held nowadays. The market acquired its original state and witnessing rapid growth during the forecast period 2021-2027.
The Asia Pacific local anaesthetic drug market is bifurcated by drug molecules, route of administration, distribution channel and country.
The drug molecules like bupivacaine, lidocaine, benzocaine, ropivacaine, prilocaine, Chloroprocaine and other local anaesthetic drugs are comprised in the Asia Pacific local anaesthetic drug market. In which bupivacaine is also contributing in the growth of Asia Pacific local anaesthetic drug market. Bupivacaine is prescription-based medication which used for numbing of targeted body part or injected into the spinal canal’s epidural space. It blocks the nerve impulses which send signal to brain. It is available in various brand names like Marcaine and Sensorcaine. The half-life of bupivacaine is 3.1 hrs in adults and 8.1 hrs in neonates and has onset of action in 15 minutes and last up to two to eight hours.
The route of administrations like intravenous local anaesthesia, topical local anaesthesia and ophthalmic local anaesthesia are comprised in the Asia Pacific local anaesthetic drug market. In which intravenous route is expected to dominate the market in 2020. The intravenous administration implies rapid onset of sensory and motor block, reduced intraoperative and tourniquet pain, prolonged post-surgical analgesia and minimum side effects are owing to propel growth of segment in Asia Pacific local anaesthetic drug market. Additionally, intravenous local anaesthetic have better intestinal motility and reduced opioid consumptions.
The distribution channels like online pharmacies, retail pharmacies and hospital pharmacies are comprised in Asia Pacific local anaesthetic drug market. In which hospital pharmacies is expected to dominate the market in 2020. The high patient outflow of outpatients is propelling the growth of Asia Pacific local anaesthetic drug market. The adoption of technically advanced healthcare equipment is also refuelling the growth of Asia Pacific local anaesthetic drug market. The growing population is also elevating growth of Asia Pacific local anaesthetic drug market.
The Asia Pacific local anaesthetic drug market is studied for countries like India, Japan, China, Australia and South Korea. In which China and India are anticipated to dominate the market in 2020. The rising healthcare expenditure is propelling the growth of Asia Pacific local anaesthetic drug market. The rising surgical procedures in region is also refuelling the growth of Asia Pacific local anaesthetic drug market. Adoption of technologically advanced healthcare equipment is also elevating growth of Asia Pacific local anaesthetic drug market. The rising collaboration and new product launch is also contributing in the growth of Asia Pacific local anaesthetic drug market.
The key players operating in the local anaesthetic drug market are Advanced Pharma Inc., Akorn Inc., Aspen Pharmacare, Baxter International Inc., Fresenius Kabi, Glenmark Pharmaceuticals Inc., Mylan, Novartis Ag, Pacira Pharmaceutical, Pfizer Inc., Sagent Pharmaceutical and Teva Pharmaceutical Industries Ltd. among the others.
November 2018: The Septodont announced lauching of Dentapen electronic syringe for application in dental anaesthesia.
April 2018: The B. Braun Medical Inc. launched its first FDA- approved local anaesthetic for use in spinal anaesthesia named Clorotekal® which comprised of Chloroprocaine hydrochloride.
• Astrazeneca offers various anaesthetic products in its product portfolio like Carbocaine (mepivacaine). Citanest (prilocaine), Dipitan (propofol), EMLA (lidocaine + prilocaine), Marcaine (bupivacaine), Naproin (ropivacaine) along with Xylocaine (lidocaine/ lignocaine).
• Glenmark Pharmaceutical marketed lidocaine ointment name Fougera for topical anaesthetic purpose comprised of lidocaine ointment USP, 5%.
The study comprised of local anaesthetic drug market. In which different segment of market are analysed. The market segments like drug molecules, route of administrations and distribution channels are analysed in the study. The study also imparts the dominating segments of the market. The drug molecules segment is dominated by lidocaine. Likewise, route of administration segment is dominated by intravenous route and distribution channel is dominated by hospital pharmacies. The study also imparts the geographical section of the market and it analysed that China and India is dominating the market in 2020. The study also imparts impact of COVID-19 on local anaesthetic drug market and it concludes that there is slight slow growth of local anaesthetic drug market is experienced during the COVID-19 situation as there is several restraining factors like mismatch between demand and supply due to complete shutdown in many countries which hampered the transportation of general anaesthetic drugs. The several surgical procedures are post ponded during the time of COVID-19 pandemic. However, activities are resuming and all the pending surgeries are being held nowadays. The market acquired its original state and witnessing rapid growth during the forecast period 2021-2027. The study also analysed various key players operating in the market.
Why to buy this report
